OyaGen: OyaGen, Inc. Announces a Compound in Development with Broad Antiviral Activity Against Coronaviruses, including SARS-CoV-2
OyaGen, Inc. announced today new unpublished results from collaborative research with the National Institute of Allergy and Infectious Diseases' Integrated Research Facility at Fort Detrick, MD
Read full article »
OyaGen focuses on the discovery, development and commercialization of pharmaceutical therapies to exploit RNA editing and DNA editing enzymes.
Read more